Business
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injuryVancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine...
About this update from Optimi Health Corp.
[{"type":"text","content":"The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury","length":233,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken initial steps toward a federal policy framework intended to accelerate research and patient access to psychedelic drug products.","length":625,"tagName":"p"},{"type":"text","content":"Ibogaine is a naturally occurring alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central and West Africa. It has been studied for its potential to interrupt opioid withdrawal and craving, and for its effects on substance-use disorders, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI). A 2024 Stanford-led study of U.S. Special Operations veterans, published in Nature Medicine, reported reductions in PTSD, depression, anxiety, and functional disability in a cohort following a single ibogaine treatment protocol.","length":568,"tagName":"p"},{"type":"text","content":"Optimi is commercial-stage in Australia, where authorized physicians are actively prescribing the Company's MDMA for PTSD and its naturally derived psilocybin for treatment-resistant depression (TRD). In parallel, the Company supplies pharmaceutical-grade MDMA and psilocybin to clinical trials and special access programs globally.","length":336,"tagName":"p"},{"type":"text","content":"As part of its U.S. market readiness strategy, Optimi obtained an FDA Establishment Identifier (FEI) number in 2025, supporting its ability to engage with U.S. regulatory and commercial pathways as they evolve.","length":210,"tagName":"p"},{"type":"text","content":"On April 18, 2026, U.S. President Donald Trump signed an Executive O...